Arginase - 1 - Based Diagnosis as Indicator of the Risk of HBV - Related HCC

Bita Moudi1,2,*

1Infectious Diseases and Tropical Medicine Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
2Department of Histology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

*Corresponding author: Bita Moudi, M.Sc., Department of Histology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran. Postal Code: 98167 - 43175, Tel: +98-5433295794, Fax: +98-5433295794, E-mail: bita.moodi@yahoo.com

Received 2017 April 02; Accepted 2017 April 25.

Keywords: Hepatocellular Carcinoma, Chronic Hepatitis B, Arginase - 1

Dear Editor,

Hepatocellular carcinoma (HCC) is a common primary liver malignancy worldwide with a poor prognosis (1) and is the third leading cause of cancer-related deaths (2).

Chronic hepatitis B (HBV) infection, which can cause liver inflammation, has been seen in many individuals with HCC. In addition, fibrosis and cirrhosis are inevitable complications of the infection, which leads to the death of a patient (3, 4).

Early diagnosis of this can prevent the death of a patient and is a crucial factor in the treatment process (5).

It seems that urea cycle enzymes are reliable markers for hepatocytes. For example, arginase - 1 (Arg - 1), which mainly concentrates in periportal hepatocytes (6), is one of the urea cycle enzymes that is expressed in a healthy liver (7).

Chrzanowska et al., assessed Arg - 1 expression by advanced PCR methods and found decreased expression of Arg - 1 in cirrhotic nodules and HCCs (8).

Recently, we found that the expressions of Arg - 1 significantly reduced in patients with HBV-related HCC compared to the patients with only HBV, which can probably manage the diagnosis process of HCC in a way that is time-consuming. The specificity of Arg - 1, among all groups we tested, was 88.4%. Our data emphasized that Arg - 1 can be one of the best markers for HCC on fine-needle aspiration specimens. The results of this study will be released. We also reported Arg - 1 as a very sensitive marker for hepatocytes, which supports Benjamin et al., conclusion as well (9).

Benjamin et al., (9) found the overall sensitivity to be about 96.0% for Arg - 1 in hepatocytes and hepatocellular neoplasms. In addition, all HCCs in their study were reactive for Arg - 1. Moreover, the study of nonhepatocellular tumors revealed that only 2 non-HCC tumors were reactive for Arg - 1.

Furthermore, proper combination of Arg - 1, with some reliable biomarkers such as HepPar - 1 could increase the specificity, accuracy, and precision of natural history of HBV-related HCC diagnosis. We proposed an algorithm to study the natural history of HCC using 2 markers of malignancy (HepPar - 1 and Arg - 1) and found that the respective specificity of Arg - 1 + HepPar - 1 is 100% when we examined HCC cases that were infected previously with HBV.

In another study, Timek et al., (10) performed a triplet algorithm including Arg - 1, hepatocyte paraffin - 1 (Hep-Par1), and glypican - 3 on liver specimens. They showed that none of the nonhepatic tumor cases were positive for Arg - 1. A total of 19 HCCs samples responded to all three markers, 9 samples responded with only 1 or 2 markers and only 1 case was negative for all 3 markers. Timek suggested the use of 3 markers in differentiating between HCC and metastatic carcinoma.

In conclusion, most of the Arg - 1 studies demonstrated that Arg - 1 has a high sensitivity and specificity in diagnosis of HBV-related HCC and it seems that Arg - 1 can probably be used in detecting HBV-infected patients, which are susceptible to HCC. Arg - 1 can develop as an identifier biomarker in pathology of HCC. In addition, the proper combination of Arg - 1 and some well-known and reliable biomarkers is more effective in the study of natural history of the liver malignancy in different stages.

References

1. Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H, Alavian SM, Lankarani KB, Farrokh P, et al. Concomitant use of heat-shock protein 70, glu-
tamine synthetase and glypican-3 is useful in diagnosis of HBV-related hepatocellular carcinoma with higher specificity and sensitivity. *Eur J Histochem*. 2018;62(1):2859. doi: 10.4081/ejh.2018.2859. [PubMed: 29569872]. [PubMed Central: PMC5806503].

2. Li H, Wang S, Wang G, Zhang Z, Wu X, Zhang T, et al. Yes-associated protein expression is a predictive marker for recurrence of hepatocellular carcinoma after liver transplantation. *Dig Surg*. 2014;31(6):468–78. doi: 10.1159/000370252. [PubMed: 25632982].

3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology*. 2007;132(7):2557–76. doi: 10.1053/j.gastro.2007.04.061. [PubMed: 17570226].

4. Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H. Impact of host gene polymorphisms on susceptibility to chronic hepatitis B virus infection. *Infect Genet Evol*. 2016;44:94–105. doi: 10.1016/j.meegid.2016.06.043. [PubMed: 27346643].

5. Tawada A, Kanda T, Yokosuka O. Current and future directions for treating hepatitis B virus infection. *World J Hepatol*. 2015;7(1):354–52. doi: 10.4254/wjh.v7.i1.354.[PubMed: 25608593]. [PubMed Central: PMC4462692].

6. Sekine S, Ogawa R, McManus MT, Kanai Y, Hebrok M. Dicer is required for proper liver zonation. *J Pathol*. 2009;219(3):365–72. doi: 10.1002/path.2606. [PubMed: 19718708].

7. Multhaupt H, Fritz P, Schumacher K. Immunohistochemical localisation of arginase in human liver using monoclonal antibodies against human liver arginase. *Histochemistry*. 1987;87(5):465–70. [PubMed: 332144].

8. Chrzanowska A, Gajewska B, Baranczyk-Kuzma A. Arginase isoenzymes in human cirrhotic liver. *Acta Biochim Pol*. 2009;56(3):465–9. [PubMed: 19636440].

9. Yan BC, Gong C, Song J, Krausz T, Tretiakova M, Hyjek E, et al. Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. *Am J Surg Pathol*. 2010;34(8):1147–54. doi: 10.1097/PAS.0b013e181e5dffa. [PubMed: 20666013]. [PubMed Central: PMC180115].

10. Timek DT, Shi J, Liu H, Lin F. Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens. *Am J Clin Pathol*. 2012;138(2):203–10. doi: 10.1309/AJCPKZC9WNHCCMU. [PubMed: 22904131].